Viking Therapeutics (VKTX) Equity Ratio (2014 - 2026)

Viking Therapeutics has disclosed Equity Ratio across 13 years of filings, most recently posting 0.83 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.83, down 15.52% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.83 (down 15.52% YoY), and the FY2025 annual result was 0.89, down 7.87% from the prior year.
• Equity Ratio came in at 0.83 for Q1 2026 at Viking Therapeutics, down from 0.89 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.98 in Q1 2025 to a low of 0.83 in Q1 2026.
• The 5-year median for Equity Ratio is 0.96 (2025), against an average of 0.93.
• Across the five-year window, Equity Ratio increased 9.65% in 2023 and retreated 15.52% in 2026, its largest moves.
• Viking Therapeutics' Equity Ratio stood at 0.86 in 2022, then gained by 9.65% to 0.95 in 2023, then advanced by 2.5% to 0.97 in 2024, then fell by 7.87% to 0.89 in 2025, then declined by 7.58% to 0.83 in 2026.
• The last three Equity Ratio figures came in at 0.83 (Q1 2026), 0.89 (Q4 2025), and 0.96 (Q3 2025), per Business Quant data.